# The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study

> **NCT06796504** · NA · RECRUITING · sponsor: **SetPoint Medical Corporation** · enrollment: 60 (estimated)

## Conditions studied

- Relapsing Remitting Multiple Sclerosis

## Interventions

- **PROCEDURE:** Procedure/Surgery: Implant Procedure
- **DRUG:** Disease-Modifying Therapies (DMTs)
- **DEVICE:** Device: Active stimulation
- **DEVICE:** Device: Non-active stimulation

## Key facts

- **NCT ID:** NCT06796504
- **Lead sponsor:** SetPoint Medical Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-31
- **Primary completion:** 2027-12-31
- **Final completion:** 2030-09-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06796504

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06796504, "The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06796504. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*